AZD1208

1204144-28-4

C21H21N3O2S

DMSO : 28.5 mg/mL (75.10 mM; Need ultrasonic and warming)

JAK/STAT Signaling; Autophagy

AZD1208 is a novel, orally bioavailable, highly selective PIM kinases inhibitor. In Vitro: AZD1208 shows good antiproliferative activity in a megakaryoblastic leukemia cell line, MOLM-16, with GI₅₀ values less than 100 nM^[1]. AZD1208 (10 uM) inhibits the growth of Ramos cells, and at 1 uM, strongly inhibits PIM kinases in all cell at 1 uM. AZD1208 induces apoptosis, and PIM2 knockdown is mainly associated with an alteration of the cell cycle^[2]. The combination of AZD1208 and AZD2014 rapidly activates AMPKalpha, a negative regulator of translation machinery through mTORC1/2 signaling in AML cells; profoundly inhibits AKT and 4EBP1 activation; and suppresses polysome formation^[3].